Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 4:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Inflammation Corneal Clear all
Recruiting Phase 2 Interventional

Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

NCT06919081
View directory record Official record
Conditions
Persistent Corneal Epithelial Defect, Corneal Epithelial Disorders
Interventions
Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome, Vehicle Control
Drug · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 23, 2026, 4:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Contact Lenses and Infiltrative Keratitis

NCT02186431
View directory record Official record
Conditions
Keratitis
Interventions
senofilcon A
Device
Lead sponsor
State University of New York College of Optometry
Other
Eligibility
18 Years to 30 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Sep 23, 2026, 4:41 AM EDT
Withdrawn Phase 1 Interventional

Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions

NCT02042027
View directory record Official record
Conditions
Corneal Neovascularization, Corneal Graft Failure, Anterior Segment Inflammation
Interventions
Gamunex-C
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Sep 23, 2026, 4:41 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK

NCT02227147
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
rhNGF 20µg/ml, Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Loma Linda, California • Los Angeles, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Sep 23, 2026, 4:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Microbiologic Alterations of the Conjunctiva of Hot Tub-soaking Ophthalmologists

NCT03987178
View directory record Official record
Conditions
Conjunctivitis, Bacterial, Keratitis Bacterial
Interventions
Dunk, Exposure to Hot Tub
Behavioral · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Sep 23, 2026, 4:41 AM EDT
Withdrawn Phase 4 Interventional

Repository Corticotropin Injection in Keratoconjunctivitis Sicca

NCT03398018
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
repository corticotropin injection
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Sep 23, 2026, 4:41 AM EDT
Recruiting Phase 3 Interventional

Parasitic Ulcer Treatment Trial

NCT06213649
View directory record Official record
Conditions
Acanthamoeba Keratitis
Interventions
Polyhexamethylene biguanide (PHMB), Topical corticosteroid, Topical placebo
Drug · Other
Lead sponsor
Jeremy Keenan, MD, MPH
Other
Eligibility
8 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
13
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 23, 2026, 4:41 AM EDT
Completed Phase 4 Interventional Results available

Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya

NCT05918406
View directory record Official record
Conditions
Dry Eye, Keratoconjunctivitis Sicca
Interventions
Nasal Guide
Combination Product
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
2
States / cities
Edison, New Jersey • Woodland Park, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Sep 23, 2026, 4:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of the Presence and Extent of Corneal Disturbance Associated With B+L Biotrue MPS Used With B+L PureVision Lenses

NCT01268306
View directory record Official record
Conditions
Keratitis
Interventions
B+L Biotrue MPS and B+L PureVision
Device
Lead sponsor
Epstein, Arthur B., OD, FAAO
Individual
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 21, 2016 · Synced Sep 23, 2026, 4:41 AM EDT
Completed No phase listed Observational

Screening for Research Subjects With Anterior Segment Diseases

NCT00088348
View directory record Official record
Conditions
Eye Diseases
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 23, 2026, 4:41 AM EDT
Completed Phase 4 Interventional Results available

Impact of Acthar on Everyday Life of Participants With Severe Keratitis

NCT04169061
View directory record Official record
Conditions
Keratitis
Interventions
Acthar
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Glendale, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Sep 23, 2026, 4:41 AM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of the PXL Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Position

NCT04213885
View directory record Official record
Conditions
Keratoconus, Unstable, Ectasia Corneal, Bacterial Keratitis
Interventions
PXL 330 Platinum device/Riboflavin
Combination Product
Lead sponsor
Eye Specialists of Indiana
Other
Eligibility
12 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Sep 23, 2026, 4:41 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate

NCT04573647
View directory record Official record
Conditions
Neurotrophic Ulcer, Neurotrophic Keratitis, Neurotrophic Corneal Ulcer, Neurotrophic Keratoconjunctivitis
Interventions
Cenegermin-Bkbj 0.002% Ophthalmic Solution [OXERVATE]
Drug
Lead sponsor
Sight Medical Doctors PLLC
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 23, 2026, 4:41 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Dry Eye Assessment and Management: Feasibility Study

NCT01102257
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
Omega-3 EFA Supplement, Olive Oil
Drug
Lead sponsor
Asbell, Penny, M.D.
Individual
Eligibility
18 Years to 90 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2012 · Synced Sep 23, 2026, 4:41 AM EDT
Not yet recruiting Phase 3 Interventional

RB-PDT for Fusarium Keratitis: The LUMIERE Study

NCT07743489
View directory record Official record
Conditions
Fusarium Keratitis
Interventions
Rose Bengal Photodynamic Therapy, Sham RB-PDT
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
2
States / cities
Palo Alto, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 23, 2026, 4:41 AM EDT
Terminated Not applicable Interventional

Omega-3 Fatty Acid Supplements and Dry Eye

NCT01213342
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Omega-3 Fatty Acid, Soybean Soft Gels
Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Sep 23, 2026, 4:41 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Studying the Relationship Between Contact Lens Packaging Solutions and Bacterial Binding to Surface Eye Cells

NCT01104961
View directory record Official record
Conditions
Corneal Ulcer
Interventions
Contact lens packaging solution, Balanced salt solution (BSS)
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 38 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Sep 23, 2026, 4:41 AM EDT
Completed Phase 2 Interventional Results available

REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients

NCT04276558
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
Udonitrectag, Vehicle
Drug · Other
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
9
States / cities
Crystal River, Florida • Gainesville, Florida • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 23, 2026, 4:41 AM EDT
Completed Phase 1 Interventional

A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease

NCT01733992
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, R348 Ophthalmic Solution, 1.0%, Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2014 · Synced Sep 23, 2026, 4:41 AM EDT
Completed No phase listed Observational Results available

Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease

NCT00717418
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
cyclosporine ophthalmic emulsion 0.05%, artificial tears
Drug
Lead sponsor
Allergan
Industry
Eligibility
Not listed
Enrollment
781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Wilson, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Sep 23, 2026, 4:41 AM EDT
Completed Phase 4 Interventional

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery

NCT04521140
View directory record Official record
Conditions
Corneal Edema, Corneal Defect, Corneal Transplant, Penetrating KeratoPlasty, Anterior Chamber Inflammation, Ocular Pain, Intraocular Pressure
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp
Drug
Lead sponsor
Nicole Fram M.D.
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 23, 2026, 4:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Refractory Corneal Infection

NCT02068430
View directory record Official record
Conditions
Corneal Ulcers
Interventions
Riboflavin 0.1%, UV-X™ Illumination System
Drug · Other
Lead sponsor
Stephen Trokel
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 23, 2026, 4:41 AM EDT
Completed No phase listed Observational

Nerve Growth Factor for the Treatment of Cornea Disease

NCT04552730
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
Cenegermin-Bkbj
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Sep 23, 2026, 4:41 AM EDT
Terminated Not applicable Interventional

Corneal Neurotization as a Treatment for Neurotrophic Keratopathy

NCT05809245
View directory record Official record
Conditions
Neurotrophic Corneal Ulcer, Neurotrophic Keratitis, Cranial Nerve V Diseases
Interventions
Corneal neurotization
Procedure
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 23, 2026, 4:41 AM EDT